45°
Daratumumab is an investigational human anti-CD38 monoclonal antibody currently being evaluated as a potential multiple myeloma monotherapy treatment.
“We employ every resource available to accelerate the development of novel treatments to improve and meaningfully extend the lives of multiple myeloma patients – especially those at greatest risk of disease progression and few or no treatment options,” said Walter Capone, chief executive officer and president of the MMRF, in a press release. “Together with our collaborators, we are working to quickly advance the development of the most promising therapies. Our collaboration with Janssen on this landmark EAP (expanded access program) is just one example of how we are speeding access to novel therapies to patients who need them most.”
EAPs allow pharmaceutical companies to make investigational therapies available to patients with serious or life-threatening diseases that are not helped by currently available treatment options, according to a press release. The multicenter, open-label daratumumab EAP is available to multiple myeloma patients who are double refractory to both a proteasome inhibitor and an immunomodulatory drug or who have received three or more prior lines of therapy, according to a press release.
Patients should contact their physician if they believe they are eligible or if they want to learn more. Additional information can be found here.
For more information about the MMRF, go here.
Click here to follow Daily Voice Norwalk and receive free news updates.
